Erin M. McIntyre
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Erin M. McIntyre has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Adrian R. Black
Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, USA
17 shared publications - Arjun Dhir
University of Nebraska Medical Center 1 Department of Biochemistry and Molecular Biology Omaha, Nebraska
17 shared publications - Arnob Mitro
University of Nebraska Medical Center 1 Department of Biochemistry and Molecular Biology Omaha, Nebraska
17 shared publications - Calvin Lam
Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center
17 shared publications - Chinmay M. Jogdeo
University of Nebraska Medical Center 3 Center for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, College of Pharmacy Omaha, Nebraska
17 shared publications - David Oupický
University of Nebraska Medical Center
17 shared publications
Latest Publications
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from PAMD-Ch17, a Polymeric Analog of Plerixafor, Induces Mitochondrial Dysfunction in T-ALL Cells Independent of CXCR4
Supplementary Figure 2. PAMD-Ch17 blocks the CXCR4 receptor.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from PAMD-Ch17, a Polymeric Analog of Plerixafor, Induces Mitochondrial Dysfunction in T-ALL Cells Independent of CXCR4
Supplementary Figure 2. PAMD-Ch17 blocks the CXCR4 receptor.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from PAMD-Ch17, a Polymeric Analog of Plerixafor, Induces Mitochondrial Dysfunction in T-ALL Cells Independent of CXCR4
Supplementary Table 1. Primary Patient Samples.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from PAMD-Ch17, a Polymeric Analog of Plerixafor, Induces Mitochondrial Dysfunction in T-ALL Cells Independent of CXCR4
Supplementary Table 1. Primary Patient Samples.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Data from PAMD-Ch17, a Polymeric Analog of Plerixafor, Induces Mitochondrial Dysfunction in T-ALL Cells Independent of CXCR4
PAMD-Ch17 is a polymer composed of the CXCR4 inhibitor AMD3100/Plerixafor with a cholesterol modification. In previous work, we showed that PAMD-Ch17, but not AMD3100, induces cell death and differentiation in mouse acute myeloid leukemia cells. To investigate the mechanism of PAMD-Ch17’s novel antileukemic effects, we tested PAMD-Ch17 against a panel of human leukemia cell lines and found that PAMD-Ch17 is effective against a variety of acute leukemias, with T-cell acute lymphoblastic leukemia (T-ALL) cell lines being highly sensitive. Surprisingly, CXCR4 knockout T-ALL cells were equally sensitive to PAMD-Ch17. Using a fluorescently tagged PAMD-Ch17, we found that the drug colocalized to mitochondria. We also found that PAMD-Ch17 induced changes in the expression of genes related to mitochondrial function, increased levels of mitochondrial superoxide, and decreased mitochondrial membrane potential. Using Seahorse assays, we found that PAMD-Ch17 decreased baseline oxygen consumption, ATP production, and proton leakage. In addition, we identified ATP synthase subunits as binding partners of PAMD-Ch17 and showed that the polymer, but not AMD3100, inhibited ATP synthase activity. In mouse primary T-ALL, but not healthy bone marrow cells, PAMD-Ch17 induced both mitochondrial superoxide and cell death. Using human bone marrow organoids, we found that PAMD-Ch17 induced mitochondrial superoxide and cell death in T-ALL cells from patients, but not in healthy stromal and hematopoietic cells. Collectively, our results indicate that PAMD-Ch17 has antileukemic effects against T-ALL cells but not healthy cells, likely mediated through a CXCR4-independent, mitochondrial-based mechanism. These findings support the further development of PAMDs as potential therapeutics for patients with T-ALL.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from PAMD-Ch17, a Polymeric Analog of Plerixafor, Induces Mitochondrial Dysfunction in T-ALL Cells Independent of CXCR4
PAMD-Ch17 is a polymer composed of the CXCR4 inhibitor AMD3100/Plerixafor with a cholesterol modification. In previous work, we showed that PAMD-Ch17, but not AMD3100, induces cell death and differentiation in mouse acute myeloid leukemia cells. To investigate the mechanism of PAMD-Ch17’s novel antileukemic effects, we tested PAMD-Ch17 against a panel of human leukemia cell lines and found that PAMD-Ch17 is effective against a variety of acute leukemias, with T-cell acute lymphoblastic leukemia (T-ALL) cell lines being highly sensitive. Surprisingly, CXCR4 knockout T-ALL cells were equally sensitive to PAMD-Ch17. Using a fluorescently tagged PAMD-Ch17, we found that the drug colocalized to mitochondria. We also found that PAMD-Ch17 induced changes in the expression of genes related to mitochondrial function, increased levels of mitochondrial superoxide, and decreased mitochondrial membrane potential. Using Seahorse assays, we found that PAMD-Ch17 decreased baseline oxygen consumption, ATP production, and proton leakage. In addition, we identified ATP synthase subunits as binding partners of PAMD-Ch17 and showed that the polymer, but not AMD3100, inhibited ATP synthase activity. In mouse primary T-ALL, but not healthy bone marrow cells, PAMD-Ch17 induced both mitochondrial superoxide and cell death. Using human bone marrow organoids, we found that PAMD-Ch17 induced mitochondrial superoxide and cell death in T-ALL cells from patients, but not in healthy stromal and hematopoietic cells. Collectively, our results indicate that PAMD-Ch17 has antileukemic effects against T-ALL cells but not healthy cells, likely mediated through a CXCR4-independent, mitochondrial-based mechanism. These findings support the further development of PAMDs as potential therapeutics for patients with T-ALL.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from PAMD-Ch17, a Polymeric Analog of Plerixafor, Induces Mitochondrial Dysfunction in T-ALL Cells Independent of CXCR4
Supplementary Figure 5. PAMD-Ch17 dysregulates genes different from that of CXCR4 KO.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from PAMD-Ch17, a Polymeric Analog of Plerixafor, Induces Mitochondrial Dysfunction in T-ALL Cells Independent of CXCR4
Supplementary Figure 5. PAMD-Ch17 dysregulates genes different from that of CXCR4 KO.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 10 from PAMD-Ch17, a Polymeric Analog of Plerixafor, Induces Mitochondrial Dysfunction in T-ALL Cells Independent of CXCR4
Supplementary Figure 10. PAMD-Ch17’s effect on human bone marrow organoids.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 10 from PAMD-Ch17, a Polymeric Analog of Plerixafor, Induces Mitochondrial Dysfunction in T-ALL Cells Independent of CXCR4
Supplementary Figure 10. PAMD-Ch17’s effect on human bone marrow organoids.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from PAMD-Ch17, a Polymeric Analog of Plerixafor, Induces Mitochondrial Dysfunction in T-ALL Cells Independent of CXCR4
Supplementary Figure 4. PAMD-Ch17 induces differential expression of genes related to cholesterol biosynthesis, protein translation, and mitochondrial homeostasis.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from PAMD-Ch17, a Polymeric Analog of Plerixafor, Induces Mitochondrial Dysfunction in T-ALL Cells Independent of CXCR4
Supplementary Figure 4. PAMD-Ch17 induces differential expression of genes related to cholesterol biosynthesis, protein translation, and mitochondrial homeostasis.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 11 from PAMD-Ch17, a Polymeric Analog of Plerixafor, Induces Mitochondrial Dysfunction in T-ALL Cells Independent of CXCR4
Supplementary Figure 11. Proposed Mechanism of PAMD-Ch17’s Anti-leukemic Effects.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 11 from PAMD-Ch17, a Polymeric Analog of Plerixafor, Induces Mitochondrial Dysfunction in T-ALL Cells Independent of CXCR4
Supplementary Figure 11. Proposed Mechanism of PAMD-Ch17’s Anti-leukemic Effects.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from PAMD-Ch17, a Polymeric Analog of Plerixafor, Induces Mitochondrial Dysfunction in T-ALL Cells Independent of CXCR4
Supplementary Figure 6. PAMD-Ch17 colocalizes with the mitochondria.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from PAMD-Ch17, a Polymeric Analog of Plerixafor, Induces Mitochondrial Dysfunction in T-ALL Cells Independent of CXCR4
Supplementary Figure 6. PAMD-Ch17 colocalizes with the mitochondria.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from PAMD-Ch17, a Polymeric Analog of Plerixafor, Induces Mitochondrial Dysfunction in T-ALL Cells Independent of CXCR4
Supplementary Table 2. Differentially Expressed Gene lists.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from PAMD-Ch17, a Polymeric Analog of Plerixafor, Induces Mitochondrial Dysfunction in T-ALL Cells Independent of CXCR4
Supplementary Table 2. Differentially Expressed Gene lists.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from PAMD-Ch17, a Polymeric Analog of Plerixafor, Induces Mitochondrial Dysfunction in T-ALL Cells Independent of CXCR4
Supplementary Table 4. Markers used to identify non-malignant cells in bone marrow organoids.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from PAMD-Ch17, a Polymeric Analog of Plerixafor, Induces Mitochondrial Dysfunction in T-ALL Cells Independent of CXCR4
Supplementary Table 4. Markers used to identify non-malignant cells in bone marrow organoids.